Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1987 1
1988 1
1989 2
1990 1
1991 1
1992 3
1994 7
1995 8
1996 4
1997 8
1998 5
1999 5
2000 6
2001 7
2002 10
2003 5
2004 15
2005 6
2006 8
2007 9
2008 5
2009 10
2010 18
2011 14
2012 17
2013 13
2014 12
2015 12
2016 11
2017 13
2018 11
2019 16
2020 17
2021 12
2022 14
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 4 Oral Cavity Mucositis or Stomatitis by Clinical Examination Classification, CTCAE"
Page 1
Abnormal p53 Immunohistochemical Patterns Shed Light on the Aggressiveness of Oral Epithelial Dysplasia.
Novack R, Zhang L, Hoang LN, Kadhim M, Ng TL, Poh CF, Kevin Ko YC. Novack R, et al. Mod Pathol. 2023 Jul;36(7):100153. doi: 10.1016/j.modpat.2023.100153. Epub 2023 Mar 9. Mod Pathol. 2023. PMID: 36906072
We included a total of 203 cases of oral epithelial dysplasia, proliferative verrucous leukoplakia, lichenoid, and commonly observed mucosal reactive lesions to evaluate their p53 immunohistochemical (IHC) staining patterns. ...We propose the term p53 abnorma …
We included a total of 203 cases of oral epithelial dysplasia, proliferative verrucous leukoplakia, lichenoid, and commonly observ …
Low-level laser therapy in treatment of chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial.
Legouté F, Bensadoun RJ, Seegers V, Pointreau Y, Caron D, Lang P, Prévost A, Martin L, Schick U, Morvant B, Capitain O, Calais G, Jadaud E. Legouté F, et al. Radiat Oncol. 2019 May 22;14(1):83. doi: 10.1186/s13014-019-1292-2. Radiat Oncol. 2019. PMID: 31118057 Free PMC article. Clinical Trial.
BACKGROUND: Low-level laser therapy (LLLT) also called Photobiomodulation therapy (PBMT) could reduce oral mucositis (OM) incidence and severity in head and neck cancer patients treated by chemoradiotherapy, however randomised data about efficacy and safety are miss …
BACKGROUND: Low-level laser therapy (LLLT) also called Photobiomodulation therapy (PBMT) could reduce oral mucositis (OM) inci …
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM, Lin JC, Razaq MA, Teixeira MM, Lövey J, Chamois J, Rueda A, Hu C, Dunn LA, Dvorkin MV, De Beukelaer S, Pavlov D, Thurm H, Cohen E. Lee NY, et al. Lancet Oncol. 2021 Apr;22(4):450-462. doi: 10.1016/S1470-2045(20)30737-3. Lancet Oncol. 2021. PMID: 33794205 Clinical Trial.
Patients aged 18 years or older, with histologically confirmed, previously untreated, locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, larynx, or oral cavity (unselected for PD-L1 status), an Eastern Cooperative Oncology Group performance sta …
Patients aged 18 years or older, with histologically confirmed, previously untreated, locally advanced squamous cell carcinoma of the oropha …
Otorhinolaryngological Toxicities of New Drugs in Oncology.
Hartl DM, Morel D, Saavedra E, Massard C, Rinaldo A, Saba NF, Ferlito A, Soria JC. Hartl DM, et al. Adv Ther. 2017 Apr;34(4):866-894. doi: 10.1007/s12325-017-0512-0. Epub 2017 Mar 17. Adv Ther. 2017. PMID: 28315206 Review.
Many new or relatively new cancer drugs-personalized anticancer agents-have been approved for use in various clinical settings in oncology or are still under evaluation in clinical trials. ...Adverse effects of the mouth/pharynx, nasal cavities, larynx, and c …
Many new or relatively new cancer drugs-personalized anticancer agents-have been approved for use in various clinical settings in onc …
Results of postoperative interstitial brachytherapy of resectable floor of mouth tumors.
Ferenczi Ö, Major T, Akiyama H, Fröhlich G, Oberna F, Révész M, Poósz M, Polgár C, Takácsi-Nagy Z. Ferenczi Ö, et al. Brachytherapy. 2021 Mar-Apr;20(2):376-382. doi: 10.1016/j.brachy.2020.10.008. Epub 2020 Nov 26. Brachytherapy. 2021. PMID: 33250304 Review.
The incidence of local Grade 1, 2, and 3 mucositis was 25%, 64%, and 11%, respectively. Grade 4 side effect, that is soft tissue necrosis occurred in four cases (9%). ...
The incidence of local Grade 1, 2, and 3 mucositis was 25%, 64%, and 11%, respectively. Grade 4 side effect, tha …
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Chaudhry HM, Bruce AJ, Wolf RC, Litzow MR, Hogan WJ, Patnaik MS, Kremers WK, Phillips GL, Hashmi SK. Chaudhry HM, et al. Biol Blood Marrow Transplant. 2016 Apr;22(4):605-616. doi: 10.1016/j.bbmt.2015.09.014. Epub 2015 Sep 26. Biol Blood Marrow Transplant. 2016. PMID: 26409924 Free article. Review.
Severe mucositis was defined as either grades 2 to 4 or grades 3 and 4, depending on the studies' definition of severity. ...Besides NCI and WHO grading scales, other scales included in the studies were Oral Mucositis Index, …
Severe mucositis was defined as either grades 2 to 4 or grades 3 and 4, depending on the studies' definit …
Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers.
Villa A, Vollemans M, De Moraes A, Sonis S. Villa A, et al. Support Care Cancer. 2021 Oct;29(10):6061-6068. doi: 10.1007/s00520-021-06177-x. Epub 2021 Mar 31. Support Care Cancer. 2021. PMID: 33788003 Clinical Trial.
When patients had severe OM (WHO score 3), 99.6% (521/523) of the CTCAE OM assessments had scores of 3 or 4 (kappa 0.98; 95%CI: 0.98-0.999) and 97.7% of the RTOG ones (511/523) had scores of 3 or 4 (kappa 0.69; 95%CI: 0.62-0.75). Among pa …
When patients had severe OM (WHO score 3), 99.6% (521/523) of the CTCAE OM assessments had scores of 3 or 4 (kap …
Photobiomodulation and photodynamic therapy for the treatment of oral mucositis in patients with cancer.
Pires Marques EC, Piccolo Lopes F, Nascimento IC, Morelli J, Pereira MV, Machado Meiken VM, Pinheiro SL. Pires Marques EC, et al. Photodiagnosis Photodyn Ther. 2020 Mar;29:101621. doi: 10.1016/j.pdpdt.2019.101621. Epub 2019 Dec 10. Photodiagnosis Photodyn Ther. 2020. PMID: 31841687
In the PBM-T group, low-level laser was applied to 61 points in the oral cavity, once weekly for 4 weeks (wavelength 660 nm, power 100 mW, energy density 142 J/cm2, spot energy 4 J, irradiation time 40 s). In the PBM-T + PDT group, in addition to PBM-T …
In the PBM-T group, low-level laser was applied to 61 points in the oral cavity, once weekly for 4 weeks (wavelength 66 …
Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer: A Systematic Review.
Sayles C, Hickerson SC, Bhat RR, Hall J, Garey KW, Trivedi MV. Sayles C, et al. Nutr Clin Pract. 2016 Apr;31(2):171-9. doi: 10.1177/0884533615611857. Epub 2015 Oct 27. Nutr Clin Pract. 2016. PMID: 26507188 Review.
It significantly reduced the incidence of grade 2, 3, or 4 mucositis and/or reduced weight loss as well as the duration, time of onset, and/or maximum grade of mucositis. ...CONCLUSION: In summary, the favorable efficacy and low toxicity of o …
It significantly reduced the incidence of grade 2, 3, or 4 mucositis and/or reduced weight loss as well as the duration …
Assessment and prevalence of concomitant chemo-radiotherapy-induced oral mucositis in patients with oral squamous cell carcinoma.
Minhas S, Sajjad A, Chaudhry RM, Zahid H, Shahid A, Kashif M. Minhas S, et al. Turk J Med Sci. 2021 Apr 30;51(2):675-684. doi: 10.3906/sag-2007-131. Turk J Med Sci. 2021. PMID: 33155791 Free PMC article.
Clinical examination and procedure of oral cavity were performed before, on days 5, 17, and at the end of treatment. ...Oral mucositis is frequently related to adverse clinical outcomes, affecting the patient's quality of life. ...
Clinical examination and procedure of oral cavity were performed before, on days 5, 17, and at the end of treatm …
281 results